Filing Flows › ENvue Medical (FEED) › Q1 2026 › vs Q1 2025
ENvue Medical (FEED) Q1 2026 vs Q1 2025 (year over year)
ENvue Medical's revenue fell $372K (-36%) from $1.0M in Q1 2025 to $653K in Q1 2026. The biggest changes: Nano Vibronix −$388K (-42%); ENvue +$16K (+16%).
ENvue Medical, Q1 2026: revenue $653K (-36% year over year), operating margin -568.3%, net loss $3.8M, operating cash flow −$4.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Nano Vibronix | $534K | $922K | −$388K | -42% |
| ENvue | $119K | $103K | $16K | +16% |
| Revenue | $653K | $1.0M | −$372K | -36% |
| Net loss | $3.8M | $1.9M | $1.9M | +104% |
| Costs & expenses | $4.5M | $2.9M | $1.6M | +54% |
| Operating costs | $4.4M | $2.9M | $1.5M | +52% |
| Interest & other, net | $78K | $5K | $73K | 16× |
| Income tax | $33K | $15K | $18K | +120% |
| Research & development | $468K | $530K | −$62K | -12% |
| Sales & marketing | $772K | $349K | $423K | +121% |
| General & admin | $2.4M | $1.3M | $1.1M | +80% |
| Operating cash sources | $4.5M | $1.4M | $3.2M | +233% |
| Depreciation & amortization | $217K | $18K | $199K | 12× |
| Cash used in operations | $4.3M | $1.3M | $3.0M | +221% |
| Net loss absorbed | $3.8M | $1.9M | $1.9M | +104% |
| Working capital & other | $707K | −$511K | $1.2M | — |
Questions
How much did ENvue Medical's revenue grow year over year in Q1 2026?
ENvue Medical's revenue fell $372K (-36%) from $1.0M in Q1 2025 to $653K in Q1 2026.
What drove ENvue Medical's revenue change in Q1 2026?
Nano Vibronix −$388K (-42%); ENvue +$16K (+16%).